Mirum Pharmaceuticals is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), two life-threatening pediatric liver diseases. With the addition of Bluejay’s hepatitis drug pipeline, Mirum is poised to be a broader liver health company.

On January 26, 2026, Mirum closed on the acquisition of Fund V portfolio company, Bluejay Therapeutics. Under the terms of the transaction, RiverVest Fund V became a shareholder in Mirum.